Patents by Inventor Elisabeth Han

Elisabeth Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240142683
    Abstract: The present disclosure relates to structured protective windows that have high transmission efficiency and can isolate light between different sections of the window. The structured protective windows are less prone to glass breakage compared to conventional protective windows that are typically used to protect and isolate light transmitting and light receiving components in LiDAR exterior automotive applications.
    Type: Application
    Filed: March 24, 2022
    Publication date: May 2, 2024
    Applicants: SCHOTT Corporation, SCHOTT AG
    Inventors: Oliver Sohr, Sebastian Leugner, Kevin Tabor, Elisabeth Han, Hauke Esemann
  • Publication number: 20240124478
    Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, CS, R2, and R3 are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: November 23, 2021
    Publication date: April 18, 2024
    Inventors: Yongxin Han, Elisabeth Hennessy, Andrew J. Hoover, Jesus Moreno, David L. Sloman, Uma Swaminathan, Yingchun Ye
  • Publication number: 20240083913
    Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, M, L, CY, Cz, R1, R2, R3, R4, R2a, Ry, Rz, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: May 3, 2023
    Publication date: March 14, 2024
    Inventors: Indu Bharathan, Symon Gathiaka, Yongxin Han, Xiaoshen Ma, Ryan D. Otte, David L. Sloman, Thomas H. Graham, Timothy Henderson, Elisabeth Hennessy, Anandan Palani
  • Publication number: 20240012197
    Abstract: The present disclosure relates to light isolating arrays (can also be called “light pipes” or “light pipe arrays”) that enable high transmission efficiency and isolation of light from one location, for example a lens, to another location, for example an array of photodetector diodes (each a “PD”). The light isolating arrays can provide optical isolation of the input light and can eliminate cross talk thus enhancing the resolution via increased contrast of the incoming signal. The light isolating arrays can also protect the PD's from contamination when used in outdoor devices.
    Type: Application
    Filed: November 16, 2021
    Publication date: January 11, 2024
    Applicants: SCHOTT Corporation, SCHOTT AG
    Inventors: Oliver Sohr, Sebastian Leugner, Kevin Tabor, Michael Dargie, Elisabeth Han